Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective... Virchows Arch (2017) 471:809–813 DOI 10.1007/s00428-017-2222-z BRIEF REPORT Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey 1 1 2 3 Zandra C. Deans & Hannah Williams & Elisabeth M. C. Dequeker & Cleo Keppens & 4 5 6 6 Nicola Normanno & Ed Schuuring & Simon J. Patton & Melanie Cheetham & 7 8,9 Rachel Butler & Jacqueline A. Hall & On behalf of IQN Path ASBL Received: 18 April 2017 /Revised: 6 July 2017 /Accepted: 14 August 2017 /Published online: 25 August 2017 The Author(s) 2017. This article is an open access publication Introduction several advantages: in the absence of suitable or sufficient tissue biopsy, it yields material for molecular analysis, can demonstrate Molecular biomarker analysis for the personalised treatment molecular resistance to targeted treatment and is an alternative to of non-small cell lung cancer (NSCLC) and colorectal cancer invasive tissue sampling [4]. Plasma ctDNA analysis may also (CRC) is becoming more common, due to the number and prove useful in cases of intra- and inter-tumour heterogeneity availability of molecular targets for predictive biomarker test- [5]. With formal approval from the European Medicine Agency ing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Virchows Archiv Springer Journals

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

Loading next page...
 
/lp/springer_journal/review-of-the-implementation-of-plasma-ctdna-testing-on-behalf-of-iqn-LU0pKWVBhh
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pathology
ISSN
0945-6317
eISSN
1432-2307
D.O.I.
10.1007/s00428-017-2222-z
Publisher site
See Article on Publisher Site

Abstract

Virchows Arch (2017) 471:809–813 DOI 10.1007/s00428-017-2222-z BRIEF REPORT Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey 1 1 2 3 Zandra C. Deans & Hannah Williams & Elisabeth M. C. Dequeker & Cleo Keppens & 4 5 6 6 Nicola Normanno & Ed Schuuring & Simon J. Patton & Melanie Cheetham & 7 8,9 Rachel Butler & Jacqueline A. Hall & On behalf of IQN Path ASBL Received: 18 April 2017 /Revised: 6 July 2017 /Accepted: 14 August 2017 /Published online: 25 August 2017 The Author(s) 2017. This article is an open access publication Introduction several advantages: in the absence of suitable or sufficient tissue biopsy, it yields material for molecular analysis, can demonstrate Molecular biomarker analysis for the personalised treatment molecular resistance to targeted treatment and is an alternative to of non-small cell lung cancer (NSCLC) and colorectal cancer invasive tissue sampling [4]. Plasma ctDNA analysis may also (CRC) is becoming more common, due to the number and prove useful in cases of intra- and inter-tumour heterogeneity availability of molecular targets for predictive biomarker test- [5]. With formal approval from the European Medicine Agency ing

Journal

Virchows ArchivSpringer Journals

Published: Aug 25, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off